Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Ferdows AtiqIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0002-3769-9148
Robin BlokDepartment of Haematology, Erasmus University Medical Center-Erasmus MC, Rotterdam, The Netherlands.
Calvin B van KwawegenDepartment of Haematology, Erasmus University Medical Center-Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0002-3822-1496
Anne-Marije HulshofIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0001-9688-2324
Dearbhla DohertyIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0002-9759-062X
Michelle LavinIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0003-2999-4216
Johanna G van der BomDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9095-2475
Niamh M O'ConnellNational Coagulation Centre, St James's Hospital, Dublin, Ireland.ORCID 0000-0002-7005-5328
Kevin RyanNational Coagulation Centre, St James's Hospital, Dublin, Ireland.
Saskia E M ScholsDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-2423-2829
Waander L van HeerdeDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0001-7101-8775
Mairead DoyleNational Coagulation Centre, St James's Hospital, Dublin, Ireland.
Mary ByrneNational Coagulation Centre, St James's Hospital, Dublin, Ireland.ORCID 0000-0002-0214-1718
Floor C J I Heubel-MoenenHemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, Nijmegen, The Netherlands.ORCID 0000-0002-3281-926X
Karin P M van GalenVan Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Roger J S PrestonIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0003-0108-4077
Marjon H CnossenDepartment of Pediatric Hematology and Oncology, Erasmus MC, University Medical Center-Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0003-1557-2995
Karin FijnvandraatDepartment of Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0904-4360
Ross I BakerWestern Australia Centre for Thrombosis and Haemostasis, Perth Blood Institute, Murdoch University, Perth, WA, Australia.ORCID 0000-0002-2728-6788
Karina MeijerDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0001-9447-0465
Paula JamesDepartment of Medicine, Queen's University, Kingston, ON, Canada.ORCID 0000-0003-4649-9014
Jorge Di PaolaDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, St. Louis, MO.ORCID 0000-0002-1461-2871
Jeroen EikenboomDivision of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-3268-5759
Frank W G LeebeekDepartment of Haematology, Erasmus University Medical Center-Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0001-5677-1371
James S O'DonnellIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0003-0309-3313
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
abstractPrevious reports have highlighted that some patients with low von Willebrand factor (VWF) with significant bleeding were diagnosed based on an isolated but persistent reduction in plasma VWF activity levels in the 30 to 50 IU/dL range. These patients had plasma VWF antigen (VWF:Ag) levels >50 IU/dL and thus had qualitative low VWF (low VWF-QL) rather than quantitative low VWF. Although the clinical importance of functional VWF defects in type 2 von Willebrand disease (VWD) is well recognized, the translational implications of mild functional defects in patients with low VWF-QL have not been defined. To address this clinically important question, we combined low VWF data sets from the low VWF in Ireland cohort and the low VWF in Erasmus MC studies. Overall, we observed that low VWF-QL was common and accounted for ∼50% of our combined low VWF cohort. Importantly, our findings demonstrated that many of these patients with mild isolated functional VWF defects in the 30 to 50 IU/dL range had significant bleeding phenotypes, although their plasma VWF:Ag levels were within the normal range. In addition, we further showed that low VWF-QL is a distinct clinicopathological entity compared to type 2 VWD. Finally, our studies highlighted that low VWF-QL is predominantly caused by abnormalities in VWF biosynthesis within endothelial cells that are occurring largely independent of identifiable pathological VWF sequence variants. Cumulatively, these novel observations have important clinical implications for the diagnosis and management of patients with mild functional VWF defects.
Indexed as
von Willebrand Disease, Type 2von Willebrand FactorAdultAgedCohort StudiesFemaleHemorrhageHumansMaleMiddle AgedPhenotypevon Willebrand Factor
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF. · full record | OpenQuestion